Radiation therapy (RT) is an important component in the management of breast cancer. It is recommended that up to 80% of patients with breast cancer should receive RT as part of their treatment [@b0005]. The standard of care for many years has been whole breast irradiation delivered with a long fractionated schedule over 5 to 6 weeks [@b0010]. Hypofractionation (39--42.5 Gy in 13--16 fractions) has been shown in several randomised trials to be equally efficacious when compared with those treated with traditional 5-week RT (45--50 Gy in 25--28 fractions) for patients with early breast cancer [@b0015], [@b0020] and is now considered accepted practice [@b0025], [@b0030]. In addition to clinical benefits, hypofractionation also offers other advantages including reduced burden of travelling for treatment, convenience, time, cost, quality of life and patient satisfaction.

There is urgency for improving evidence-based practice because of increasing demand for services from an ageing population, medical science developments and cost escalators [@b0035]. Substantial variation in the adoption of hypofractionation for early stage breast cancer has been observed in Australia and internationally [@b0040], [@b0045], [@b0050], [@b0055], [@b0060] despite the availability of consensus guidelines. These studies are limited to when the breast alone is treated. There have been no studies that have examined the variation in fractionation in the overall breast cancer population including early and advanced breast cancer, where nodal RT might also be part of the plan. Moreover, patient consequences and financial costs of fractionation variation for this group of patients have yet to be determined either in Australia or internationally. This study aimed to investigate the degree of variation in RT fractionation in a population-based cohort of breast cancer patients in Australia and identify factors associated with the variation, and to estimate survival outcome and cost implications.

Methods and materials {#s0005}
=====================

Study population {#s0010}
----------------

The cohort comprised all breast cancer patients who received RT in New South Wales (NSW) between 2009 and 2013. Cases were identified from a linked dataset comprising diagnosis data recorded in NSW Central Cancer Registry, the NSW Cancer Institute Electronic RT Oncology Data (extract of RT data from each NSW public and private radiation oncology facility), Admitted Patient Data Collection (APDC), and Registry of Births, Deaths and Marriages (RBDM). Probabilistic data linkage was performed by the Centre for Health Record Linkage (CHeReL). Based on the available datasets, the study period was defined from 2009 to 2013, with the date of last follow up until 2018 providing a minimum of five years potential follow up for survival analysis. The study was approved by the NSW population and health services research ethics committee.

Primary outcomes and covariables {#s0015}
--------------------------------

The primary outcome was to identity degree of variation in the use of fractionation in breast RT. For this study, two groups of fractionation regimens were defined; non-hypofractionation (dose per fraction ≤2.0 Gy), and hypofractionation (dose per fraction \>2.0 Gy).

The analysis was stratified by area of treatment; breast alone, breast + nodes, chest wall alone and chest wall + nodes. Patients were divided into two breast cancer clinical groups according to the evidence-based optimal RT fractionation model [@b0065]; Early (T1-2, N0-1, M0) and Advanced (T3-4, Nx, M0 or Tx, N2-3, M0). In addition to these clinical groups, a third group of patients with missing TNM staging data were also included for analysis. Factors associated with fractionation variation that were evaluated include patients' age at treatment, laterality, year of treatment, local health district (LHD) of residence, socioeconomic status (SES) imputed from area of residence, geographic remoteness of area of residence, and country of birth. Survival outcome was defined as 5 years overall survival.

Cost analysis {#s0020}
-------------

The method used to estimate cost per fraction has been previously calculated by our group based on a single RT department as the base case [@b0070]. In this previous study, a hybrid approach that merges features from activity-based costing (ABC) and relative value units costing (RVU) were used to provide cost estimates. ABC methodology was used to allocate costs to all RT activities associated with each patient's treatment course, while the RVUs represent the cost of each RT activity relative to the average cost of all activities and were used to achieve a weighted cost allocation. A patient's journey for the financial year was constructed by consolidating all the RT activities and their associated costs, and the average cost per activity (fraction) was determined. For breast cancer, the average cost per fraction was estimated to be AUD \$221 per fraction regardless of stage and area of treatment (breast alone, breast + nodes, chest wall alone and chest wall + nodes). Based on this, cost per treatment course for patients in this study population was estimated and potential cost saving associated with evidence-based optimal fractionation was determined. We have previously estimated and reported the evidence-based optimal number of RT fractions for cancer [@b0065], [@b0075]. The estimated optimal number of fractions for early and advanced breast cancer were 16.8 and 15.1, respectively [@b0065]. For patients with missing TNM stages, the optimal number of fractions of 16.4 for all breast cancer was used as the model includes all staging groups [@b0075].

Statistical analyses {#s0025}
--------------------

Logistic regression models were used to analyse factors associated with fractionation variation. The factors included were age, laterality, year of treatment, clinical group, SES, remoteness of residency and country of birth. Kaplan-Meier was used to analyse the association between fractionation regimen and survival on univariate analysis. Multivariable Cox proportional-hazards regression model was used to analyse these patient factors with survival. The adjusting variables included were age, laterality, year of treatment, SES, remoteness of residency and country of birth.

Results {#s0030}
=======

A total of 10,482 patients were available for analysis ([Supp Material 1](#s0050){ref-type="sec"}). Results are presented by treatment to the breast, breast + nodes and all chest wall (chest wall alone and chest wall + nodes).

7000 patients received RT to the breast alone. Hypofractionation was more likely to be delivered to older patients: 74% of patients aged ≥80 years, compared with 14% of patients aged \<40 years (*P* \< 0.001) ([Table 1](#t0005){ref-type="table"} ). Patients who received hypofractionation to the right breast (43%) were higher than those that received hypofractionation to the left breast (40%) (*P* = 0.002). The proportion of patients who received hypofractionation increased from 37% in 2009 to 49% in 2013 (*P* \< 0.001). Patients in the early stage clinical group (45%) were more likely to receive hypofractionation compared with missing stage (34%) (*P* \< 0.001). A higher proportion of hypofractionation was delivered to patients in lower SES regions (48%) compared to those in higher SES regions (28%) (*P* \< 0.001). Patients from inner regional and outer regional areas were more likely to receive hypofractionation compared with those from major cities and remote areas (*P* \< 0.001). The proportion of hypofractionation delivered to patients born in Australia (43%) was higher compared to those born overseas (39%) (*P* \< 0.001). In multivariable analyses, increasing age, laterality (right-sided), year of treatment (2013), early stage, lower SES, and inner/outer regional areas of residence were all independently associated with increased use of hypofractionation. There was a wide range in the proportion of cases who received hypofractionation across the residence LHDS, ranging from 6% to 75% ([Fig. 1](#f0005){ref-type="fig"} a).Table 1Logistic regression models to assess factors associated with use of \>2 Gy/fraction for breast.BreastFrequenciesUnivariate analysesMultivariable analyses\>2 Gy/fraction≤2 Gy/fraction(*N* = 2909, 42%)(*N* = 4091, 58%)OR (95% CI)*P* valueOR (95% CI)*P* value**Age at radiation therapy**\<0.001\<0.001 \<4033 (14%)204 (86%)0.19 (0.13--0.28)\<0.0010.19 (0.13--0.28)\<0.001 40--49283 (26%)808 (74%)0.41 (0.35--0.48)\<0.0010.40 (0.34--0.47)\<0.001 50--59672 (35%)1262 (65%)0.62 (0.55--0.71)\<0.0010.61 (0.53--0.69)\<0.001 60--691121 (46%)1315 (54%)ReferenceReference\<0.001 70--79604 (58%)432 (42%)1.64 (1.42--1.90)\<0.0011.68 (1.44--1.96)\<0.001 ≥80196 (74%)70 (26%)3.28 (2.47--4.36)\<0.0013.52 (2.62--4.72)\<0.001  **Laterality**0.002\<0.001 Left1415 (40%)2142 (60%)ReferenceReference Right1494 (43%)1949 (57%)1.16 (1.06--1.28)0.0021.20 (1.08--1.33)\<0.001  **Year**\<0.001\<0.001 2009314 (37%)529 (63%)ReferenceReference 2010549 (37%)936 (63%)0.99 (0.83--1.18)0.91.00 (0.83--1.20)0.9 2011607 (40%)894 (60%)1.14 (0.96--1.36)0.11.07 (0.89--1.29)0.5 2012612 (41%)884 (59%)1.17 (0.98--1.39)0.081.10 (0.92--1.33)0.3 2013827 (49%)848 (51%)1.64 (1.39--1.95)\<0.0011.59 (1.33--1.90)\<0.001  **Clinical group**\<0.001\<0.001 Early2097 (45%)2572 (55%)ReferenceReference Advanced30 (57%)23 (43%)1.60 (0.93--2.76)0.091.42 (0.78--2.57)0.2 Missing782 (34%)1496 (66%)0.64 (0.58--0.71)\<0.0010.68 (0.61--0.76)\<0.001  **Socioeconomic status**\<0.001\<0.001 Most disadvantaged674 (48%)717 (52%)ReferenceReference Second quintile640 (51%)605 (49%)1.13 (0.97--13.31)0.11.02 (0.86--1.20)0.8 Third quintile615 (40%)907 (60%)0.72 (0.62--0.84)\<0.0010.73 (0.63--0.86)\<0.001 Fourth quintile582 (42%)817 (58%)0.76 (0.65--0.88)\<0.0010.77 (0.65--0.91)0.002 Least disadvantaged398 (28%)1045 (72%)0.41 (0.35--0.47)\<0.0010.43 (0.36--0.51)\<0.001  **Remoteness of residency**\<0.001\<0.001 Major city1564 (36%)2793 (64%)ReferenceReference Inner regional850 (51%)826 (49%)1.84 (1.64--2.06)\<0.0011.55 (1.37--1.76)\<0.001 Outer regional484 (52%)439 (48%)1.97 (1.71--2.27)\<0.0011.47 (1.24--1.73)\<0.001 Remote/very remote11 (25%)33 (75%)0.60 (0.30--1.18)0.10.45 (0.22--0.92)0.03  **Country of birth**\<0.0010.1 Australia1964 (43%)2586 (57%)ReferenceReference Overseas945 (39%)1505 (61%)0.83 (0.75--0.91)\<0.0010.91 (0.81--1.02)0.1Fig. 1Variations in fractionation regimen by residence local health districts for (a) breast alone, (b) breast + nodes, and (c) all chest wall.

1119 patients received RT to breast + nodes. Hypofractionation was more likely to be delivered to older patients: 34% of patients aged ≥80 years, compared with 0% of patients aged \<40 years (*P* \< 0.001) ([Table 2](#t0010){ref-type="table"} ). Patients in the advanced stage clinical group were more likely to receive hypofractionation compared with early and missing stage (*P* \< 0.001). A higher proportion of hypofractionation was delivered to patients with lower SES (11%) compared to those with higher SES (2%) (*P* \< 0.001). Patients from remote/very remote areas were more likely to receive hypofractionation (25%) compared with those from major cities (5%) (*P* \< 0.001). In multivariable analyses, increasing age, advanced stage clinical group and remote areas of residence were associated with increased use of hypofractionation. There was a wide spread of hypofractionation used across the LHDS, ranging from 0 to 60% ([Fig. 1](#f0005){ref-type="fig"}b).Table 2Logistic regression models to assess factors associated with use of \> 2 Gy/fraction for breast + nodes.Breast + nodesFrequenciesUnivariate analysesMultivariable analyses\>2 Gy/fraction≤2 Gy/fraction(*N* = 95, 8%)(*N* = 1024, 92%)OR (95% CI)*P* valueOR (95% CI)*P* value**Age at radiation therapy**\<0.001\<0.001 \<400104 (100%)-------- 40--4915 (5%)265 (95%)0.54 (0.28--1.07)0.080.56 (0.28--1.14)0.1 50--5921 (7%)291 (93%)0.69 (0.37--1.28)0.20.67 (0.35--1.30)0.2 60--6923 (9%)221 (91%)ReferenceReference 70--7918 (14%)108 (86%)1.60 (0.83--3.09)0.21.40 (0.69--2.86)0.3 ≥8018 (34%)35 (66%)4.94 (2.42--10.08)\<0.0016.21 (2.81--13.75)\<0.001  **Laterality**0.60.4 Left52 (9%)531 (91%)ReferenceReference Right43 (8%)493 (92%)0.89 (0.58--1.36)0.60.81 (0.51--1.30)0.4  **Year**0.70.5 200913 (11%)104 (89%)ReferenceReference 201014 (7%)193 (93%)0.58 (0.26--1.28)0.20.48 (0.20--1.16)0.1 201122 (9%)212 (91%)0.83 (0.40--1.71)0.60.86 (0.38--1.95)0.7 201223 (9%)243 (91%)0.76 (0.37--1.55)0.40.69 (0.31--1.56)0.4 201323 (8%)272 (92%)0.68 (0.33--1.39)0.30.65 (0.29--1.44)0.3  **Clinical group**\<0.001\<0.001 Early31 (7%)399 (93%)ReferenceReference Advanced47 (16%)254 (84%)2.38 (1.47--3.85)\<0.0012.17 (1.28--3.68)0.004 Missing17 (4%)371 (96%)0.59 (0.32--1.08)0.090.75 (0.39--1.47)0.4  **Socioeconomic status**\<0.0010.007 Most disadvantaged25 (11%)209 (89%)ReferenceReference Second quintile29 (15%)159 (85%)1.52 (0.86--2.70)0.11.18 (0.61--2.30)0.6 Third quintile13 (6%)202 (94%)0.54 (0.27--1.08)0.080.51 (0.23--1.10)0.09 Fourth quintile23 (10%)204 (90%)0.94 (0.52--1.71)0.80.95 (0.47--1.91)0.9 Least disadvantaged5 (2%)250 (98%)0.17 (0.06--0.44)\<0.0010.25 (0.09--0.70)0.009  **Remoteness of residency**\<0.001\<0.001 Major city34 (5%)727 (95%)ReferenceReference Inner regional43 (17%)203 (83%)4.53 (2.81--7.29)\<0.0013.70 (2.10--6.53)\<0.001 Outer regional17 (16%)91 (84%)3.99 (2.15--7.44)\<0.0013.13 (1.48--6.60)0.003 Remote/very remote1 (25%)3 (75%)7.13 (0.72--70.32)0.096.90 (0.63--75.43)0.1  **Country of birth**0.40.3 Australia62 (9%)627 (91%)ReferenceReference Overseas33 (8%)*397 (92%)*0.84 (0.54--1.31)0.41.34 (0.79--2.26)0.3

2363 patients received RT to the chest wall. Hypofractionation was more likely to be delivered to older patients: 21% of patients aged ≥80 years, compared with 6% of patients aged \<40 years (*P* \< 0.001) ([Table 3](#t0015){ref-type="table"} ). Patients in the early stage clinical group were more likely to receive hypofractionation compared with advanced and missing stage (*P* \< 0.001). A higher proportion of hypofractionation was delivered to patients with lower SES (9%) compared to those with higher SES (3%) (*P* \< 0.001). Patients from regional areas (*P* \< 0.001) and those born in Australia (*P* \< 0.001) were also more likely to receive hypofractionation. In multivariable analyses, increasing age, early stage clinical group, higher socioeconomic status, and regional areas of residence were associated with increased use of hypofractionation. There was a wide spread of hypofractionation used across the LHDS, ranging from 0 to 42% ([Fig. 1](#f0005){ref-type="fig"}c).Table 3Logistic regression models to assess factors associated with use of \> 2 Gy/fraction for all chest wall.All chest wallFrequenciesUnivariate analysesMultivariable analyses\>2 Gy/fraction≤2 Gy/fraction(*N* = 214, 9%)(*N* = 2149, 91%)OR (95% CI)*P* valueOR (95% CI)*P* value**Age at radiation therapy**\<0.001\<0.001 \<4014 (6%)203 (94%)0.56 (0.30--1.03)0.060.81 (0.42--1.57)0.5 40--4947 (8%)580 (92%)0.66 (0.44--0.99)0.040.74 (0.48--1.16)0.2 50--5935 (6%)574 (94%)0.49 (0.32--0.77)0.0020.53 (0.33--0.85)0.009 60--6954 (11%)438 (89%)ReferenceReference 70--7940 (13%)266 (87%)1.22 (0.79--1.89)0.41.25 (0.77--2.03)0.4 ≥8024 (21%)88 (79%)2.21 (1.30--3.77)0.0043.06 (1.66--5.65)\<0.001  **Laterality**0.50.4 Left112 (9%)1074 (91%)ReferenceReference Right102 (9%)1075 (91%)0.91 (0.69--1.21)0.50.88 (0.65--1.21)0.4  **Year**0.60.9 200913 (7%)173 (93%)ReferenceReference 201044 (9%)420 (91%)1.39 (0.73--2.65)0.31.22 (0.60--2.46)0.6 201151 (9%)507 (91%)1.34 (0.71--2.52)0.41.04 (0.52--2.08)0.9 201245 (8%)513 (92%)1.17 (0.62--2.22)0.61.01 (0.50--2.03)0.9 201361 (10%)536 (90%)1.51 (0.81--2.282)0.21.08 (0.55--2.14)0.8  **Clinical group**\<0.001\<0.001 Early79 (13%)539 (87%)ReferenceReference Advanced115 (13%)776 (87%)1.01 (0.74--1.37)0.90.86 (0.61--1.21)0.4 Missing20 (2%)834 (98%)0.16 (0.10--0.27)\<0.0010.18 (0.11--0.30)\<0.001  **Socioeconomic status**\<0.001\<0.001 Most disadvantaged48 (9%)474 (91%)ReferenceReference Second quintile63 (17%)315 (83%)1.98 (1.32--2.95)\<0.0011.23 (0.78--1.92)0.4 Third quintile21 (4%)466 (96%)0.44 (0.26--0.75)0.0030.45 (0.25--0.80)0.007 Fourth quintile69 (15%)404 (85%)1.69 (1.14--2.50)0.0091.74 (1.09--2.80)0.02 Least disadvantaged13 (3%)490 (97%)0.26 (0.14--0.49)\<0.0010.43 (0.22--0.84)0.01  **Remoteness of residency**\<0.001\<0.001 Major city47 (3%)1503 (97%)ReferenceReference Inner regional122 (22%)435 (78%)8.97 (6.30--12.76)\<0.0017.60 (5.12--11.29)\<0.001 Outer regional45 (18%)202 (82%)7.12 (4.61--11.00)\<0.0016.07 (3.65--10.07)\<0.001 Remote/very remote09 (100%)--------  **Country of birth**\<0.0010.4 Australia158 (11%)1346 (89%)ReferenceReference Overseas56 (6%)803 (94%)0.59 (0.43--0.82)0.0011.18 (0.82--1.70)0.4

For early stage, there was no significant difference in the 5-year Kaplan-Meier overall survival estimate; 91.7% for \>2 Gy/fraction versus 92.5% for ≤2 Gy/fraction (*P* = 0.3). For advanced stage, the 5-year Kaplan-Meier overall survival estimate was significantly different between the 2 treatment regimens; 64.8% for \>2 Gy/fraction and 75.2% for ≤2 Gy/fraction (*P* = 0.002). For missing stage, the 5-year Kaplan-Meier overall survival estimate was 86.5% (\>2 Gy/fraction) and 86.0% (≤2 Gy/fraction) with no significant difference (*P* = 0.8) ([Fig. 2](#f0010){ref-type="fig"} ). In multivariable survival analysis, there was no difference between the two dose regimens for all staging groups at 5 years ([Supp Material 2](#s0050){ref-type="sec"}).Fig. 2Kaplan-Meier curves showing the difference in 5-year overall survival between the two fractionation regimens for early, advanced and missing stage.

An estimated \$52.1 million (Early: \$27,312,948; Advanced: \$6,639,282; Missing: \$18,081,336) was spent on this cohort of patients for their breast RT ([Table 4](#t0020){ref-type="table"} ). If these patients were treated with optimal number of fractions as per evidence based guidelines [@b0065], [@b0075], the estimated cost would be \$38.5 million. This demonstrated a potential cost savings of \$13.6 million which would be a 26% reduction in breast RT costs for this cohort.Table 4Cost analysis.No. of patients (A)Total no. of fractions treated (B)Cost per fraction (C)Estimated cost spent (B\*C)No. of optimal fractions (D)Optimal cost (A\*C\*D)Early stage5753123,588\$221\$27,312,94816.8\$21,359,738Advanced stage125930,042\$221\$6,639,28215.1\$4,201,409Missing stage355781,816\$221\$18,081,33616.4\$12,891,991  Total\$52,033,566\$38,453,138

Discussion {#s0035}
==========

This study identified a wide variability in the use of hypofractionation in RT for early and advanced breast cancer in NSW. Factors that affected the use of hypofractionation varied between the clinical groups and whether patients received RT to the breast (±nodes) or chest wall. Factors that correlated with increased use of hypofractionation in breast alone included increasing age, laterality (right-sided), later year of treatment (2013), early stage, lower SES, and inner/outer regional areas of residence. Previous studies in NSW have also identified age, laterality, year, and treating facility as factors that correlated significantly with hypofractionation use in patients with early breast cancer [@b0045], [@b0060]. Although our study and previous published studies [@b0040], [@b0045], [@b0060] showed increase in hypofractionation use over time, this rate of increase is very slow.

There are limited available data regarding the effects of hypofractionated regional nodal RT in breast RT. Reports from a randomised trial [@b0080], registry [@b0085] and institutional [@b0090], [@b0095] analyses showed that hypofractionation for nodal RT is safe and effective. In 2013, hypofractionated RT in breast + nodes was only 8%. Similarly, a low rate of hypofractionation (10%) was used for all chest wall patients, despite evidence from previous studies supporting the use of hypofractionation for postmastectomy breast cancer patients [@b0100], [@b0105]. These extreme low rates show lack of progress in the adoption of hypofractionation in these patient groups. Although the rate of hypofractionation in breast alone patients increased from 37% in 2009 to 49% in 2013, this is a small increment compared to Canadian studies that reported higher rates of adoption (69%--85%) [@b0110]. A possible reason for slow adoption of hypofractionation in Australia may be driven by the remuneration incentives in Australia, which is determined by the number of RT fractions delivered. In Canada, radiation therapy is fully covered by provincial funding and no privately funded or operated radiation treatment facilities are permitted where profit-driven motives may be less influential on clinical decision making [@b0115]. The evidence-based, patient-centered nature of the Canadian system has enabled widespread adoption of hypofractionation [@b0115].

Our study identified that the residence LHD influenced the use of hypofractionation reflecting variation between facilities, and previous studies have identified prescribing radiation oncologist as a factor [@b0045], [@b0060], [@b0120]. Prades et al [@b0120] suggested two reasons for understanding clinicians' reluctance to adopt hypofractionation regimens; (1) some clinicians perceived newer treatment techniques as 'another layer of complexity' that seemed to slow adoption of hypofractionation, (2) quality of evidence is a necessary but not a sufficient condition determining clinician's behaviour towards hypofractionation including clinical management factors, such as the role of the department head. Efforts are needed to embed a data solution for a clinical quality data repository in RT to systematically identify, interpret and respond to variation in practice. Supporting clinicians to visualise their practice in relation to their peers and evidence base, modify their prescribing habits to adhere to guidelines, and subsequently maintain this change requires effective, reproducible interventions. Evidence shows that facilitated feedback methods and models focussing on changing clinician behaviour are effective to respond to variation [@b0125].

Healthcare is increasingly recognising the relationship between reducing variation, reducing cost and improving outcomes. Leading Better Value Care (LBVC) is one of the programs that aims to accelerate value-based healthcare in NSW. It involves clinicians, networks and organisations working together on high-impact initiatives to improve patient outcomes. One of the initiatives of LBVC program is to reduce variation in the use of hypofractionated breast RT [@b0130]. This will reduce treatment time, reduce cost, improve quality of life for patients, increase RT access, and increase capacity in RT departments. Our study found that a majority of women in NSW received longer and more costly regimen. Overall, only 31% of women in our cohort received the less costly hypofractionated regimen. As expected, the total cost is reduced considerably with the reduction in number of fractions. When considering early breast cancer alone, hypofractionated schedules would have reduced the cost by about 22% compared to non-hypofractionated schedules. For advanced breast cancer, the costs would be reduced by 37% with hypofractionated schedules, while for patients with missing stage, the costs would be reduced by 29%. Treatment with hypofractionation would have resulted in a \$13.6 million savings when compared with defaulting to non-hypofractionation treatment in this cohort. Our current results support that significant reductions in cancer-related treatment costs is possible through the practice of evidence-based breast cancer care, and will further support the LBVC initiatives.

More recently, evidence from the FAST-Forward trial showed that 26 Gy in 5 fractions over 1 week is non-inferior to 40 Gy in 15 fractions over 3 weeks for local tumour control, and is as safe in terms of normal tissue effects up to 5 years for patients with early stage breast cancer [@b0135]. The 1-week schedule has major benefits over the 3-week or 5-week regimens in terms of convenience and cost for patients and for health services globally. Will this 1-week regimen also take decades to be fully introduced and practiced widely? The coronavirus disease 2019 (COVID-19) pandemic has brought some challenges to the practice of RT. Measures are now being taken to reduce the flow of patients to cancer centres and hospitals by rapidly adopting hypofractionation regimens including the FAST-Forward regimen [@b0140]. Accelerated partial breast irradiation delivered in 1 to 2 weeks has also been recommended as an effective regimen [@b0145] among appropriately selected patients. Will it take a pandemic to speed up wide adoption of less costly and cumbersome schedules? Is COVID-19 an opportunity to reduce and eliminate low-value practices in RT? It is not certain whether these changes in fractionation will persist if normal service is resumed.

There are several limitations to this study. We were unable to ascertain patients' treatment facilities, therefore LHD of patient residence was used as a surrogate and assumed to be the treatment facility. In reality, a small proportion of patients may have received treatment in a facility outside of their residence LHD. This study also included analyses of patients with missing TNM stage in routinely collected data, likely due to incomplete data received by the registries. As this group of patients accounted for 34% of this study cohort, we included them in this study to provide an overall analysis. It should also be pointed out that the cost per fraction used in this study is the average cost per fraction for breast cancer, regardless of stage and delivery techniques. The costs quoted therefore reflect the average casemix for the NSW population. The cost per fraction also accounts for cost of all activities involved in the treatment preparation and assumes that treatment costs scale linearly with the number of fractions, which may be incorrect. Inclusion of treatment preparation costs into the cost per fraction may give rise to a distortion of the costs of different fractionation schedules [@b0150]. It may be more accurate to calculate the costs incurred in the treatment preparation stage separately, however the approach may be more challenging.

Despite evidence supporting the use of hypofractionation for breast RT, it was underused between 2009 and 2013 in this Australian population-based study. Further work is ongoing to examine more recent rates. This study highlights that evidence-based practice will translate to reduced health care treatment costs. Opportunities exist for patients to receive high-quality breast RT at lower costs, and these options should be encouraged in routine clinical care. Future work is needed to increase the utilisation of hypofractionation and reduce variations in pattern of practice.
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